Additionally, with PIK3CA-mutant HER2+ being a common mutation profile in breast cancers, HER2+ inhibitors in combination with alpelisib are being investigated in multiple clinical trials [NCT04208178, NCT05230810, NCT02167854, NCT05063786]. This evidence concerns the gene ERBB2 and breast carcinoma.